GLM | Jotup

Repeat: Treatment.com AI Announces New Additions to its Medical Education Suite (MES)

Retrieved on:

Wednesday, April 17, 2024

AI Doctor, OSCE, School, OTC, Software as a service, Consultant, Benchmarking, Faculty, GLM, Student, USMLE

Treatment’s MES enhances the entire continuum of clinical content education, from simple introductory patient interactions to more advanced USMLE diagnostic evaluations and grading to complex faculty benchmarking.

Key Points:

Treatment’s MES enhances the entire continuum of clinical content education, from simple introductory patient interactions to more advanced USMLE diagnostic evaluations and grading to complex faculty benchmarking.
The suite of solutions provides support for faculty and students in both design and preparation for the OSCE (Objective Structured Clinical Examination).
The market in the US alone comprises 300 medical schools; 900 nursing schools; 227,000 students and 145,000 residents/medical students.
Both solutions are underpinned by Treatment’s AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library.

Treatment.com AI Announces New Additions to its Medical Education Suite (MES)

Retrieved on:

Wednesday, April 17, 2024

AI Doctor, OSCE, School, OTC, Software as a service, Consultant, Benchmarking, Faculty, GLM, Student, USMLE

Treatment’s MES enhances the entire continuum of clinical content education, from simple introductory patient interactions to more advanced USMLE diagnostic evaluations and grading to complex faculty benchmarking.

Key Points:

Treatment’s MES enhances the entire continuum of clinical content education, from simple introductory patient interactions to more advanced USMLE diagnostic evaluations and grading to complex faculty benchmarking.
The suite of solutions provides support for faculty and students in both design and preparation for the OSCE (Objective Structured Clinical Examination).
The market in the US alone comprises 300 medical schools; 900 nursing schools; 227,000 students and 145,000 residents/medical students.
Both solutions are underpinned by Treatment’s AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library.

Treatment.com AI partners with aiXplain Inc. to extend access to its Global Library of Medicine (GLM)

Retrieved on:

Wednesday, April 10, 2024

News, AI, Heart, OTC, Partnership, Artificial intelligence, Treatment, Artificial intelligence in healthcare, GLM, Organization, Medical device

Treatment has partnered with aiXplain, the industry’s first no-code/low-code integrated AI development platform.

Key Points:

Treatment has partnered with aiXplain, the industry’s first no-code/low-code integrated AI development platform.
Over the past 7 years and in collaboration with hundreds of healthcare professionals globally, utilizing proprietary algorithms, Treatment has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM).
aiXplain’s marketplace makes it possible for healthcare organizations to access Treatment’s AI engine through its development framework and enhance the quality of clinical diagnosis within their organizations across multiple platforms.
This is the first specialized AI model for the healthcare industry to join our marketplace, expanding the versatility of our AI platform across sectors."

Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

Retrieved on:

Wednesday, April 10, 2024

PALM BEACH, Fla., April 10, 2024 /PRNewswire/ -- With the increase in life expectancy, people need more medical help and care. AI-enabled technologies can help people to live healthier and longer lives. Artificial Intelligence (A.I.) has a great demand in the healthcare industry. Healthcare providers turn to tech companies for expertise in adopting AI, and naturally, demand for such expertise makes competition among the latter highly intensive. A report from binariks.com projected that the global artificial intelligence in the healthcare market was valued at USD 16.3 billion in 2022 and is expected to grow at a CAGR of 40.2% to reach USD 173.55 billion by 2029. The report said: "The healthcare AI market is experiencing a remarkable and significant surge in its growth and acceptance. Here are some insights about AI and the healthcare market: North America controls the market and has a strong presence of key players; Using AI-powered medical imaging technologies is a huge trend among healthtech companies; Medical businesses continue to grow and expand, so mergers and acquisitions are becoming very common. Larger players are acquiring smaller companies to enhance their AI capabilities or extend their market coverage; The integration of AI with complementary technologies like robotics or blockchain promotes precision medicine and transforms healthcare delivery; and Generative AI-powered virtual assistants and chatbots are experiencing rising requests due to their 24/7 support opportunities." Active tech companies in the markets this week include Treatment AI, Inc. (OTCQB: TREIF) (CSE: TRUE), Medtronic (NYSE:MDT), NVIDIA (NASDAQ: NVDA), HEALWELL AI Inc. (OTCQX: HWAIF) (TSX: AIDX), Lantern Pharma Inc. (NASDAQ: LTRN).

Key Points:

A report from binariks.com projected that the global artificial intelligence in the healthcare market was valued at USD 16.3 billion in 2022 and is expected to grow at a CAGR of 40.2% to reach USD 173.55 billion by 2029.
The report said: "The healthcare AI market is experiencing a remarkable and significant surge in its growth and acceptance.
Based on components, the global AI in the healthcare market can be divided into software, hardware, and services.
The software segment has the largest share and is expected to have the fastest growth."

Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

Retrieved on:

Wednesday, April 10, 2024

PALM BEACH, Fla., April 10, 2024 /PRNewswire/ -- With the increase in life expectancy, people need more medical help and care. AI-enabled technologies can help people to live healthier and longer lives. Artificial Intelligence (A.I.) has a great demand in the healthcare industry. Healthcare providers turn to tech companies for expertise in adopting AI, and naturally, demand for such expertise makes competition among the latter highly intensive. A report from binariks.com projected that the global artificial intelligence in the healthcare market was valued at USD 16.3 billion in 2022 and is expected to grow at a CAGR of 40.2% to reach USD 173.55 billion by 2029. The report said: "The healthcare AI market is experiencing a remarkable and significant surge in its growth and acceptance. Here are some insights about AI and the healthcare market: North America controls the market and has a strong presence of key players; Using AI-powered medical imaging technologies is a huge trend among healthtech companies; Medical businesses continue to grow and expand, so mergers and acquisitions are becoming very common. Larger players are acquiring smaller companies to enhance their AI capabilities or extend their market coverage; The integration of AI with complementary technologies like robotics or blockchain promotes precision medicine and transforms healthcare delivery; and Generative AI-powered virtual assistants and chatbots are experiencing rising requests due to their 24/7 support opportunities." Active tech companies in the markets this week include Treatment AI, Inc. (OTCQB: TREIF) (CSE: TRUE), Medtronic (NYSE:MDT), NVIDIA (NASDAQ: NVDA), HEALWELL AI Inc. (OTCQX: HWAIF) (TSX: AIDX), Lantern Pharma Inc. (NASDAQ: LTRN).

Key Points:

A report from binariks.com projected that the global artificial intelligence in the healthcare market was valued at USD 16.3 billion in 2022 and is expected to grow at a CAGR of 40.2% to reach USD 173.55 billion by 2029.
The report said: "The healthcare AI market is experiencing a remarkable and significant surge in its growth and acceptance.
Based on components, the global AI in the healthcare market can be divided into software, hardware, and services.
The software segment has the largest share and is expected to have the fastest growth."

Treatment.com AI welcomes the Federal Government's announcement of a plan to fund $2.4 billion in its upcoming budget towards Artificial Intelligence (AI) Adoption

Retrieved on:

Monday, April 8, 2024

Agriculture, Federation, Patient, Health care, AI, Software, Treatment, OTC, GLM, Artificial intelligence, Medical device

The federal government’s announcement indicates an imminent consultation with industry on a new AI Compute Access Fund and an accompanying strategy to expand the sector in Canada.

Key Points:

The federal government’s announcement indicates an imminent consultation with industry on a new AI Compute Access Fund and an accompanying strategy to expand the sector in Canada.
As a Canadian company utilizing AI to positively disrupt the healthcare sector, Treatment welcomes this announcement.
The AI healthcare market, valued at $11 billion in 2021, is projected to be worth $187 billion in 2030.
In turn, this will have a positive impact on costs and cost allocation for our Healthcare organizations and governing bodies.

GoldenTree Asset Management Announces $1.3 Billion in Commitments for Third CLO Equity Fund

Retrieved on:

Monday, April 1, 2024

Asset Management, Professional Services, Finance, CLO, Partner (business rank), GoldenTree Asset Management, CBO, Lisp (programming language), Insurance, RIAS, AUM, IRR, Fund, GLM, AAA

GoldenTree Asset Management (“GoldenTree”), a global asset management firm with over $54 billion in assets under management, today announced the closing of $1.3 billion in commitments on its third CLO strategy (“GLM III” or the “Fund”).

Key Points:

GoldenTree Asset Management (“GoldenTree”), a global asset management firm with over $54 billion in assets under management, today announced the closing of $1.3 billion in commitments on its third CLO strategy (“GLM III” or the “Fund”).
GLM III is a continuation of the GoldenTree Loan Management (“GLM”) program that began in 2016, bringing aggregate commitments across the entire GLM program (i.e., GLM I, II, and III) to over $2.625 billion.
“Demand for our CLO equity has increased as investors recognize the value it can create within their portfolio,” she continued.
GoldenTree founded the GLM program to enhance the firm’s already top-quartile track record in CLO equity by taking a unique approach to CLO execution, optimizing both the strategy’s assets and liabilities.

Treatment.com AI Provides Corporate Update

Retrieved on:

Thursday, February 29, 2024

VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to provide a general corporate update. Treatment has been working diligently to continue its acceleration into the US market. A few key milestones the Company has accomplished are as follows:

Key Points:

Treatment Provides Platform to Support Healthcare in Nairobi, Kenya
VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to provide a general corporate update.
Dr. Kevin Peterson is the Founder and Chief Medical Officer of Treatment.com AI Inc.
Whilst utilizing AI, the GLM has been curated & evaluated by 150+ physicians globally to be correct, reliable and accurate.
Treatment’s platform provides clinical decision support to assist the healthcare workers in making an accurate diagnosis.

GoldenTree Asset Management Announces Closing of $449 Million CLO Under GLM Strategy

Retrieved on:

Monday, February 26, 2024

Banking, Asset Management, Professional Services, Finance, GLM, Investment, Wells Fargo, CLO, Morgan Stanley, Lisp (programming language), BofA Securities, AAA, GoldenTree Asset Management, Appellate court

GLM III, LP (“GLM III”) and its affiliated investment manager GoldenTree Asset Management LP (along with other affiliated investment managers “GoldenTree”), announced the closing of a $449 million collateralized loan obligation (“CLO”) to be managed by GLM III.

Key Points:

GLM III, LP (“GLM III”) and its affiliated investment manager GoldenTree Asset Management LP (along with other affiliated investment managers “GoldenTree”), announced the closing of a $449 million collateralized loan obligation (“CLO”) to be managed by GLM III.
With the closing of this CLO, GoldenTree Loan Management US CLO 19 (“GLM US CLO 19”), GoldenTree has issued 25 CLOs totaling over $14 billion under its GLM CLO strategy.
Since its inception in January 2017, the GLM strategy was intended to be compliant with applicable Risk Retention regulations.
GLM US CLO 19 will initially be backed by a 96% ramped $434 million portfolio of primarily senior secured loans as of closing and will have a five-year reinvestment period and a two-year non call period.

GoldenTree Asset Management Hires Head of Corporate Strategy

Retrieved on:

Monday, November 27, 2023

GoldenTree Asset Management (“GoldenTree”), a global asset management firm with over $51 billion in assets under management, today announced the hiring of Shawn Mathew as Partner and Head of Corporate Strategy, a newly created role.

Key Points:

GoldenTree Asset Management (“GoldenTree”), a global asset management firm with over $51 billion in assets under management, today announced the hiring of Shawn Mathew as Partner and Head of Corporate Strategy, a newly created role.
He joins GoldenTree from Sixth Street, where he was a Managing Director responsible for Corporate Strategy, Financial Planning and Corporate Accounting.
View the full release here: https://www.businesswire.com/news/home/20231127384341/en/
Shawn Mathew, Partner and Head of Corporate Strategy, GoldenTree Asset Management (Photo: Business Wire)
Steve Tananbaum, GoldenTree’s Founder, Managing Partner and Chief Investment Officer noted, “We are pleased to have Shawn join us to help drive GoldenTree’s strategic growth and corporate initiatives in close coordination with our Executive Committee.
Mathew said, “I am thrilled to join GoldenTree as the Head of Corporate Strategy.